13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Adenosine-to-inosine RNA editing by ADAR1 is essential for normal murine erythropoiesis

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adenosine deaminases that act on RNA (ADARs) convert adenosine residues to inosine in double-stranded RNA. In vivo, ADAR1 is essential for the maintenance of hematopoietic stem/progenitors. Whether other hematopoietic cell types also require ADAR1 has not been assessed. Using erythroid- and myeloid-restricted deletion of Adar1, we demonstrate that ADAR1 is dispensable for myelopoiesis but is essential for normal erythropoiesis. Adar1-deficient erythroid cells display a profound activation of innate immune signaling and high levels of cell death. No changes in microRNA levels were found in ADAR1-deficient erythroid cells. Using an editing-deficient allele, we demonstrate that RNA editing is the essential function of ADAR1 during erythropoiesis. Mapping of adenosine-to-inosine editing in purified erythroid cells identified clusters of hyperedited adenosines located in long 3’-untranslated regions of erythroid-specific transcripts and these are ADAR1-specific editing events. ADAR1-mediated RNA editing is essential for normal erythropoiesis.

          Related collections

          Author and article information

          Journal
          0402313
          3651
          Exp Hematol
          Exp. Hematol.
          Experimental hematology
          0301-472X
          1873-2399
          5 August 2016
          01 July 2016
          October 2016
          01 October 2017
          : 44
          : 10
          : 947-963
          Affiliations
          [a ]St. Vincent’s Institute of Medical Research, Fitzroy, Victoria, Australia
          [b ]Department of Medicine, St. Vincent’s Hospital, University of Melbourne, Fitzroy, Victoria, Australia
          [c ]Taconic Biosciences, Cologne, Germany
          [d ]Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology and Stem Cell Program, Children’s Hospital Boston, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA
          [e ]Department of Genetics, Stanford University, Stanford, CA, USA
          [f ]Center for Pediatric Biomedical Research, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA
          [g ]Victorian Cancer Cytogenetics Service, St. Vincent’s Hospital, Fitzroy, Victoria, Australia
          [h ]Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Heidelberg, Germany
          [i ]Howard Hughes Medical Institute, Boston, MA, USA
          [j ]Department of Genetics and Yale Stem Cell Center, Yale University, New Haven, CT, USA
          Author notes
          Offprint requests to: Carl R. Walkley, St. Vincent’s Institute, 9 Princes Street, Fitzroy, Victoria 3065, Australia; cwalkley@ 123456svi.edu.au
          Article
          PMC5035604 PMC5035604 5035604 nihpa800885
          10.1016/j.exphem.2016.06.250
          5035604
          27373493
          0c6fae07-9e67-4632-a037-f27da65f854a
          History
          Categories
          Article

          Comments

          Comment on this article